Managers
Technology, Media and Communications (TMC) global investment bank Drake Star Partners ranks tenth in TMT Global Midcap Cross Border by Activity, and second in TMT Europe Midcap Ranking by Activity in 2017 year to date.
These results reflect Drake Star Partners’ ongoing growth and expanding global reach, following a series of recent announcements including the firm’s record H1 2017 results and San Francisco office launch.
Drake Star’s Co-CEO Marc Deschamps says: “This represents a strong third-party endorsement in favor of our new type of banking structure. With an integrated global team supported by cloud workshare and intelligence tools, we
KKR is to invest in Shenzhen Suishou Technology’s Series C funding round to support the Company’s expansion across China.
Shenzhen Suishou Technology is the provider of a personal finance management platform in China.
Suishou’s partnership with KKR expands the Company’s group of world-class investors, which include Sequoia Capital, Fosun Group and Source Code Capital.
Suishou enables individuals to better manage their personal finances by providing them with a one-stop mobile destination to track spending, organise budgets, and manage credit card usage. Suishou’s popular mobile applications include personal bookkeeping app Suishouji and fully automated credit card manager Cardniu. The
Lexington Partners, an independent manager of secondary acquisition funds, has held the final close of Lexington Middle Market Investors IV and associated vehicles (LMMI IV) at USD2.66 billion.
The fund, which commenced investing at the beginning of 2017, exceeded its initial USD2 billion target and accepted commitments up to its hard cap. LMMI IV is the fourth fund in Lexington’s specialised middle market series.
LMMI IV will acquire growth capital, small, and middle market buyout interests in the global secondary market. In addition to portfolio and single-interest acquisitions, LMMI IV will target general partner-led transactions such as spin-outs, restructurings,
BaltCap Infrastructure Fund (BInF) has signed an engineering, procurement and construction (EPC) contract with Axis Technologies to develop its first infrastructure project – a 48MW biomass plant in Vilnius.
The deal was signed in Vilnius during the Pan-Baltic Infrastructure Summit 2017.
The EPC agreement, worth EUR16 million, states that a 48MW biomass plant near Gariūnai should be built and become operational by the beginning of 2019. According to estimates, this power plant will generate nearly 10 per cent of Vilnius heat demand.
“Advanced pipeline of potential infrastructure investments accumulated over the last few years enabled us to sign the
IK Investment Partners’ (IK) IK VII Fund has reached an agreement with private equity funds managed by Bridgepoint to sell Evac Group, a provider of integrated waste, wastewater, and water management systems for the marine, offshore and building industries.
Evac designs and markets environmentally friendly waste and wastewater collection and treatment systems for the marine, offshore and building industries. The Company has successfully carried out over 20,000 marine, 2,000 offshore and 2,000 building projects for customers around the world. It has employees in Brazil, China, Finland, France, Germany, Korea, Norway, Sweden and the USA, as well as representatives in more
SL Capital Partners (SL Capital), a private markets arm of global asset manager Aberdeen Standard Investments, has agreed to acquire Nederlandse Aardolie Maatschappij BV’s (NAM) 18 per cent interest in the Noordgastransport (NGT) Extension system, a pipeline transporting natural gas that is principally produced from the Dutch Continental Shelf.
The system has been operated by Engie since inception.
The NGT system incorporates a 178km 36” pipeline constructed in 1975, a 140km 36” extension constructed in 1999 and a processing plant located onshore at Uithuizen. The system connects approximately 75 platforms of different operators to the processing facility.
After
LNC Therapeutics, a company specialising in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has closed a EUR6.5 million C series funding round.
This new round, co-led by Seventure Partner, brings together a consortium of historic investors and a family office. Since its creation in 2010, LNC Therapeutics has raised a total of EUR16.5 million.
“This funding round of EUR6.5 million establishes LNC Therapeutics as a key player in the treatment of obesity and metabolic disorders through an action on the gut microbiota,” says Jean-Luc Treillou, LNC Therapeutics’ CEO.
Keensight Capital has acquired a stake in I-Tracing (“the company”), an independent specialist in cybersecurity solutions. As a new shareholder in the company, Keensight Capital joins the two founding managers, Théodore-Michel Vrangos and Laurent Charveriat.
Based in Puteaux, France, with more than 100 employees, I-Tracing is a company specializing in the security and traceability of digital information, with a service offering structured around four areas of expertise: audit & forensics: IT systems vulnerability testing and weak points analysis; integration: integration partnerships with specialised publishers; managed services: maintenance and operation of security systems; and SOC (Security Operations Center): incident prevention, detection
Sumeru Equity Partners (SEP) has led a USD45 million (USD) equity financing round in Kyriba, a provider of cloud treasury and financial management solutions, alongside existing investors Bpifrance, Iris Capital, Daher Capital and HSBC.
“SEP’s expertise in fast-growth SaaS solution providers, and their impressive track record for investing in successful technology market leaders, makes them the perfect strategic partner for Kyriba,” says Jean-Luc Robert, Chairman and CEO of Kyriba. “We are seeing strong global demand for modernizing treasury and financial operations, and are thrilled to receive the support of SEP and our existing strategic partners to help accelerate our growth.”
SEP
Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced it has completed a USD25 million Series B financing.
This unique financing event was supported by an international syndicate of accredited investors, including physicians, healthcare professionals, and medical device experts. The Company’s novel cardiac imaging technology is under clinical investigation to help physicians assess the presence of coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents, or cardiac stress.
“Heart disease is the leading cause of death globally, with one
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
